Article citationsMore>>

Otsuka Pharmaceutical Co. (2015) Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY— ABILIFY for Extended-Release Injectable Suspension, for Intramuscular Use—Indicated for Schizophrenia. https://www.otsuka.co.jp/en/company/release/2015/0326_03.html

has been cited by the following article:

Follow SCIRP
Twitter Facebook Linkedin Weibo
Contact us
+1 323-425-8868
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top